3 results
Approved WMOCompleted
1. The primary efficacy objective is to evaluate whether rivaroxaban, in doses of 10 mg or 20 mg, is superior to ASA 100 mg in the prevention of the primary efficacy outcome (i.e. fatal or non-fatal symptomatic recurrent venous thromboembolism).2.…
Approved WMOCompleted
To assess PK of MPhs and MP.
Approved WMOPending
Evaluate the effect of pediatric asthma eHealth care on the healthcare utilization, asthma outcomes and quality of life.